These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 29769203)

  • 1. Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial.
    Sharma A; Cannon CP; White WB; Liu Y; Bakris GL; Cushman WC; Zannad F
    J Am Heart Assoc; 2018 May; 7(11):. PubMed ID: 29769203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin.
    White WB; Wilson CA; Bakris GL; Bergenstal RM; Cannon CP; Cushman WC; Heller SK; Mehta CR; Nissen SE; Zannad F; Kupfer S;
    Hypertension; 2016 Sep; 68(3):606-13. PubMed ID: 27480840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
    White WB; Cannon CP; Heller SR; Nissen SE; Bergenstal RM; Bakris GL; Perez AT; Fleck PR; Mehta CR; Kupfer S; Wilson C; Cushman WC; Zannad F;
    N Engl J Med; 2013 Oct; 369(14):1327-35. PubMed ID: 23992602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.
    White WB; Bakris GL; Bergenstal RM; Cannon CP; Cushman WC; Fleck P; Heller S; Mehta C; Nissen SE; Perez A; Wilson C; Zannad F
    Am Heart J; 2011 Oct; 162(4):620-626.e1. PubMed ID: 21982652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care).
    Cavender MA; White WB; Jarolim P; Bakris GL; Cushman WC; Kupfer S; Gao Q; Mehta CR; Zannad F; Cannon CP; Morrow DA
    Circulation; 2017 May; 135(20):1911-1921. PubMed ID: 28246236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial.
    Sharma A; Vaduganathan M; Ferreira JP; Liu Y; Bakris GL; Cannon CP; White WB; Zannad F
    J Am Heart Assoc; 2020 Jan; 9(1):e012797. PubMed ID: 31902327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
    Clifton P
    Clin Ther; 2014 Dec; 36(12):2072-2079. PubMed ID: 25453730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial.
    Bergmark BA; Cannon CP; White WB; Jarolim P; Liu Y; Bonaca MP; Zannad F; Morrow DA
    Diabetes Obes Metab; 2017 Jul; 19(7):962-969. PubMed ID: 28195387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial.
    Heller SR; Bergenstal RM; White WB; Kupfer S; Bakris GL; Cushman WC; Mehta CR; Nissen SE; Wilson CA; Zannad F; Liu Y; Gourlie NM; Cannon CP;
    Diabetes Obes Metab; 2017 May; 19(5):664-671. PubMed ID: 28058763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke.
    Li YR; Tsai SS; Chen DY; Chen ST; Sun JH; Chang HY; Liou MJ; Chen TH
    Cardiovasc Diabetol; 2018 Jan; 17(1):2. PubMed ID: 29301579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome.
    Cavender MA; White WB; Liu Y; Massaro JM; Bergenstal RM; Mehta CR; Zannad F; Heller S; Cushman WC; Cannon CP
    Clin Cardiol; 2018 Aug; 41(8):1022-1027. PubMed ID: 29652078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial.
    White WB; Heller SR; Cannon CP; Howitt H; Khunti K; Bergenstal RM;
    Am J Med; 2018 Jul; 131(7):813-819.e5. PubMed ID: 29581078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
    Zannad F; Cannon CP; Cushman WC; Bakris GL; Menon V; Perez AT; Fleck PR; Mehta CR; Kupfer S; Wilson C; Lam H; White WB;
    Lancet; 2015 May; 385(9982):2067-76. PubMed ID: 25765696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the Risk of Hospitalization for Heart Failure With Dipeptidyl Peptidase-4 Inhibitors, Saxagliptin, Alogliptin, and Sitagliptin in Patients With Type 2 Diabetes, Using an Alternative Measure to the Hazard Ratio.
    Kaneko M; Narukawa M
    Ann Pharmacother; 2017 Jul; 51(7):570-576. PubMed ID: 28622738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial.
    Shimada YJ; Cannon CP; Liu Y; Wilson C; Kupfer S; Menon V; Cushman WC; Mehta CR; Bakris GL; Zannad F; White WB;
    Am Heart J; 2016 May; 175():18-27. PubMed ID: 27179720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus.
    Elharram M; Sharma A; White W; Bakris G; Rossignol P; Mehta C; Ferreira JP; Zannad F
    Am Heart J; 2020 Nov; 229():40-51. PubMed ID: 32916607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus.
    White WB; Pratley R; Fleck P; Munsaka M; Hisada M; Wilson C; Menon V
    Diabetes Obes Metab; 2013 Jul; 15(7):668-73. PubMed ID: 23489301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial.
    Ferreira JP; Rossignol P; Bakris G; Mehta C; White WB; Zannad F
    Cardiovasc Diabetol; 2021 Sep; 20(1):187. PubMed ID: 34521390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin.
    Capuano A; Sportiello L; Maiorino MI; Rossi F; Giugliano D; Esposito K
    Drug Des Devel Ther; 2013; 7():989-1001. PubMed ID: 24068868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.
    Covington P; Christopher R; Davenport M; Fleck P; Mekki QA; Wann ER; Karim A
    Clin Ther; 2008 Mar; 30(3):499-512. PubMed ID: 18405788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.